Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL5448175 | 0.90 | ACHE (0.40) | ACHEKDM4EALDH1A1MEN1CYP3A4 | |
| Bromide SCHEMBL5446114 | 0.88 | KDM4E (0.31) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5445993 | 0.88 | KDM4E (0.31) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| SCHEMBL5444525 | 0.87 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL5446074 | 0.79 | KDM4E (0.35) | KDM4ERXFP1NPSR1 | |
| SCHEMBL18103972 | 0.77 | L3MBTL1 (0.44) | KDM4EALDH1A1MEN1CYP3A4CYP2C9 | |
| Trifluoromethanesulfonic Acid SCHEMBL5455690 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL5450114 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1 | |
| Bromide SCHEMBL5443574 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1 | |
| SCHEMBL5449865 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | claimed |
| US-20070021615-A1 | Imidazolium salts that can be immobilized | MERCK PATENT GMBH (DE) | 2007-01-25 | — | — | US | disclosed |
| EP-1658297-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GmbH (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005016940-A1 | IMIDAZOLIUM SALTS THAT CAN BE IMMOBILIZED | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021615-A1 | Imidazolium salts that can be immobilized | IDH1, IDH3B, MIF | ACHE 3129/4885KDM4E 1831/4885ALDH1A1 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.